Robert J. Lutz

11.1k total citations · 3 hit papers
116 papers, 8.7k citations indexed

About

Robert J. Lutz is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Robert J. Lutz has authored 116 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Radiology, Nuclear Medicine and Imaging, 44 papers in Oncology and 33 papers in Molecular Biology. Recurrent topics in Robert J. Lutz's work include Monoclonal and Polyclonal Antibodies Research (29 papers), HER2/EGFR in Cancer Research (24 papers) and Cell death mechanisms and regulation (8 papers). Robert J. Lutz is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (29 papers), HER2/EGFR in Cancer Research (24 papers) and Cell death mechanisms and regulation (8 papers). Robert J. Lutz collaborates with scholars based in United States, Germany and Netherlands. Robert J. Lutz's co-authors include Thomas W. Chittenden, Robert L. Dedrick, Walter A. Blättler, John M. Lambert, Michael Sinensky, Toshinori Ito, Shigeomi Shimizu, Masashi Narita, Hikaru Matsuda and Yoshihide Tsujimoto and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Robert J. Lutz

113 papers receiving 8.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

2008 1.3k citations Walter A. Blättler, John M. Lambert et al. Cancer Research profile →
Bax interacts with the permeability transition pore to induce permeability transition and cytochromecrelease in isolated mitochondria

1998 827 citations Thomas W. Chittenden, Robert J. Lutz et al. profile →
Induction of apoptosis by the Bcl-2 homologue Bak

1995 644 citations Thomas W. Chittenden, Robert J. Lutz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert J. Lutz United States	42	4.2k	3.2k	2.4k	988	648	116	8.7k
Alice L. Yu United States	56	6.1k 1.4×	2.8k 0.9×	815 0.3×	2.1k 2.1×	915 1.4×	297	11.9k
Paul Nathan United Kingdom	46	3.6k 0.8×	3.8k 1.2×	818 0.3×	1.1k 1.1×	524 0.8×	272	7.9k
Pier Giorgio Natali Italy	61	5.3k 1.2×	3.1k 1.0×	1.7k 0.7×	2.6k 2.6×	473 0.7×	260	11.3k
Dennis E. Hallahan United States	66	6.5k 1.5×	3.2k 1.0×	2.8k 1.1×	1.3k 1.3×	668 1.0×	267	13.3k
Shinichi Kitada United States	59	7.6k 1.8×	3.2k 1.0×	656 0.3×	2.8k 2.8×	731 1.1×	114	11.9k
Didier Decaudin France	39	3.6k 0.9×	1.8k 0.6×	363 0.1×	1.2k 1.2×	375 0.6×	148	7.0k
Robert C. Rees United Kingdom	39	2.2k 0.5×	1.9k 0.6×	391 0.2×	2.2k 2.3×	401 0.6×	222	5.7k
Christian C. Haudenschild United States	59	4.0k 0.9×	907 0.3×	1.2k 0.5×	1.2k 1.2×	638 1.0×	145	12.1k
Mayumi Ono Japan	61	7.4k 1.7×	4.0k 1.3×	606 0.2×	1.7k 1.8×	379 0.6×	214	12.1k
Theo M. Luider Netherlands	48	4.8k 1.1×	958 0.3×	415 0.2×	941 1.0×	490 0.8×	268	8.1k

Countries citing papers authored by Robert J. Lutz

Since Specialization

Citations

This map shows the geographic impact of Robert J. Lutz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Lutz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Lutz more than expected).

Fields of papers citing papers by Robert J. Lutz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Lutz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Lutz. The network helps show where Robert J. Lutz may publish in the future.

Co-authorship network of co-authors of Robert J. Lutz

This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Lutz. A scholar is included among the top collaborators of Robert J. Lutz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Lutz. Robert J. Lutz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Deckert, Jutta, et al.. (2025). IKS04, a CanAg-Targeting Antibody–Drug Conjugate with Pyrrolobenzodiazepine, Shows Enhanced Efficacy with Unconjugated Antibody Coadministration in Animal Models. Molecular Cancer Therapeutics. 24(12). 1845–1855.

Deckert, Jutta, et al.. (2023). IKS03, a Novel CD19-Targeted Antibody Drug Conjugate, Induces Target Dependent In Vivo Cell Killing of B-Cell Lymphoma Xenografts By DNA Crosslinking. Blood. 142(Supplement 1). 1438–1438. 1 indexed citations

Lutz, Robert J., et al.. (2017). An Application of Linear Programming In Performance Evaluation. The Academy of Educational Leadership Journal. 21(1). 1. 1 indexed citations

Ab, Olga, Kathleen R. Whiteman, Laura M. Bartle, et al.. (2015). IMGN853, a Folate Receptor-α (FRα)–Targeting Antibody–Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. Molecular Cancer Therapeutics. 14(7). 1605–1613. 160 indexed citations

Lutz, Robert J.. (2015). Targeting the folate receptor for the treatment of ovarian cancer. Translational Cancer Research. 4(1). 118–126. 41 indexed citations

Kovtun, Yelena, Charlene A. Audette, Michele Mayo, et al.. (2010). Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance. Cancer Research. 70(6). 2528–2537. 194 indexed citations

Amaral, Juan, et al.. (2010). Sustained Subconjunctival Protein Delivery Using a Thermosetting Gel Delivery System. Journal of Ocular Pharmacology and Therapeutics. 26(1). 55–64. 38 indexed citations

Lutz, Robert J. & Kathleen R. Whiteman. (2009). Antibody-maytansinoid conjugates for the treatment of myeloma. mAbs. 1(6). 548–551. 52 indexed citations

Erickson, Hans K., Peter U. Park, Wayne C. Widdison, et al.. (2006). Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing. Cancer Research. 66(8). 4426–4433. 421 indexed citations

10.

Kim, Hyuncheol, Karl G. Csaky, Peng Yuan, et al.. (2006). SAFETY AND PHARMACOKINETICS OF A PRESERVATIVE-FREE TRIAMCINOLONE ACETONIDE FORMULATION FOR INTRAVITREAL ADMINISTRATION. Retina. 26(5). 523–530. 51 indexed citations

11.

Lutz, Robert J., Hongsheng Xie, Wayne C. Widdison, et al.. (2005). HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice. Cancer Research. 65. 334–335. 5 indexed citations

12.

Kim, Hyuncheol, Martin J. Lizak, Ginger Tansey, et al.. (2005). Study of Ocular Transport of Drugs Released from an Intravitreal Implant Using Magnetic Resonance Imaging. Annals of Biomedical Engineering. 33(2). 150–164. 54 indexed citations

13.

Park, Juyoung, Peter M. Bungay, Robert J. Lutz, et al.. (2005). Evaluation of coupled convective–diffusive transport of drugs administered by intravitreal injection and controlled release implant. Journal of Controlled Release. 105(3). 279–295. 95 indexed citations

14.

Yim, Peter J., Juan R. Cebral, Robert J. Lutz, et al.. (2004). Estimation of the differential pressure at renal artery stenoses. Magnetic Resonance in Medicine. 51(5). 969–977. 35 indexed citations

15.

Zhou, Xiaomai, Yimao Liu, Gillian Payne, Robert J. Lutz, & Thomas W. Chittenden. (2000). Growth Factors Inactivate the Cell Death Promoter BAD by Phosphorylation of Its BH3 Domain on Ser155. Journal of Biological Chemistry. 275(32). 25046–25051. 194 indexed citations

16.

Lutz, Robert J., Alan H. Epstein, Jack Cook, & Robert L. Dedrick. (1995). Anin VitroFlow Model to Study Streaming during Pelvic Intra-arterial Drug Infusions. Gynecologic Oncology. 59(2). 288–296. 6 indexed citations

17.

Lossef, Steven V., et al.. (1994). Comparison of Mechanical Deformation Properties of Metallic Stents with Use of Stress-Strain Analysis. Journal of Vascular and Interventional Radiology. 5(2). 341–349. 77 indexed citations

18.

Lutz, Robert J. & Donald L. Miller. (1988). Mixing studies during hepatic artery infusion in an in vitro model. Cancer. 62(6). 1066–1073. 10 indexed citations

19.

Lutz, Robert J. & Robert L. Dedrick. (1987). Implications of pharmacokinetic modeling in risk assessment analysis.. Environmental Health Perspectives. 76. 97–106. 12 indexed citations

20.

Himmelstein, Kenneth J. & Robert J. Lutz. (1979). A review of the applications of physiologically based pharmacokinetic modeling. Journal of Pharmacokinetics and Biopharmaceutics. 7(2). 127–145. 143 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact